8-K filing — Barinthus Biotherapeutics plc. (BRNS)
Filed: 2026-09-01 AccNo: 0001104659-26-104368 Size: 253 KB Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Item 8.01: Other Events
Stocks · News reference
Barinthus Biotherapeutics Q2 EPS $(0.26) Beats $(0.30) Estimate
Barinthus Biotherapeutics (NASDAQ:BRNS) reported quarterly losses of $(0.26) per share which beat the analyst consensus estimate of $(0.30) by 13.33 percent. This is a 50 percent increase over losses of $(0.52) per
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading